zanubrutinib,zandelisib
mei,kyowa kirin,beigene
['mantle,(-dismantle)', 'lymsm', 'lymphoma', 'zandelisib', 'follicular', 'zanubrutinib']
the combination of zandelisib and zanubrutinib produced high overall response rates in patients with relapsed/refractory follicular lymphoma or mantle cell lymphoma. #ash22 #lymsm #mcl 
https://t.co/bi63MIVP5D is a resource offering oncology health care professionals practical information about the changing clinical landscape.